The DREAMS Innovation Challenge was established to further PEPFAR’s commitment to reducing HIV infections among adolescent girls and young women.

The Innovation Challenge is an $85 million investment funded by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Janssen Pharmaceutica NV (Janssen), one of the Janssen pharmaceutical companies of Johnson & Johnson; and ViiV Healthcare aiming to accelerate progress toward the DREAMS target of achieving a 40 percent reduction in new HIV infections among adolescent girls and young women in the highest-burden areas of 10 sub-Saharan African countries by the end of 2017. For more information, see www.dreamspartnership.org/innovation-challenge.

DREAMS is a $385 million public-partnership, led by PEPFAR and with the support of the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences, and ViiV Healthcare, to support adolescent girls and young women to become Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe.

JSI Research & Training Institute, Inc. (JSI) will support 46 of the 56 organizations selected to execute cutting-edge programs across the 10 DREAMS countries: Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe. This group is administered by JSI and open to posts from DREAMS Innovation Challenge grantees. The views expressed do not necessarily reflect the views of the U.S. Department of State, the United States Government, or JSI.